前列腺尿道提升术治疗良性前列腺增大的采用率、安全性与再治疗率
基于Premier医疗数据库2000至2018年175,150例因良性前列腺增大/下尿路症状接受内镜手术的男性,分析前列腺尿道提升术的使用趋势、再入院和再治疗率。结果显示该术式使用率从2014年不足1%升至2018年10.4%,相比经尿道前列腺电切和前列腺光汽化,30天和90天再入院几率更低,但2年内再治疗几率更高。
要点
- 前列腺尿道提升术使用率快速上升,2018年占所有内镜手术的10.4%。
- 相比TURP和光汽化,提升术30天和90天再入院风险更低。
- 提升术2年内再治疗风险更高(OR 1.78)。
核心结论
- 前列腺尿道提升术被快速采纳,2018年占BPE/LUTS内镜手术的10.4%。
- 提升术再入院率低但2年内再治疗率高于TURP和光汽化。
研究设计与样本
- 回顾性研究,基于Premier Healthcare数据库,纳入2000至2018年接受内镜手术的175,150例男性。
- 采用多因素logistic回归分析三种最常见术式与结局的关联。
主要发现
- 前列腺尿道提升术年使用率从2014年不足1%增至2018年10.4%。
- 相比TURP和光汽化,提升术30天再入院OR 0.58(p<0.01),90天OR 0.55(p<0.01)。
- 提升术2年内再治疗OR 1.78(p<0.01)。
关键数值与推荐
- 30天再入院OR 0.58(p<0.01),90天OR 0.55(p<0.01),2年再治疗OR 1.78(p<0.01),均对比TURP和光汽化。
临床怎么用
- 选择前列腺尿道提升术时需权衡较低的再入院风险与较高的2年内再治疗风险。
- 应向患者告知提升术后2年内再治疗可能性较高。
局限性
- 回顾性数据库研究,可能存在编码偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Novel minimally invasive therapies like the prostatic urethral lift are among the many endoscopic options for the treatment of benign prostatic enlargement and lower urinary tract symptoms (BPE/LUTS). To further understand the relative uptake, complications and retreatment rates of contemporary endoscopic procedures for BPE/LUTS across diverse practice types, we performed a retrospective study of inpatient and ambulatory surgery encounters in the Premier Healthcare database. MATERIALS AND METHODS: We included men who underwent endoscopic procedures for BPE/LUTS between 2000 and 2018. We determined the utilization of endoscopic therapies for BPE/LUTS, 30-day and 90-day readmission rates, and retreatment rate. Multivariable logistic regression was used to assess the association of procedure type with outcomes for the 3 most commonly performed procedures. RESULTS: We identified 175,150 men treated with endoscopic surgery for BPE/LUTS. The annual percent utilization of the prostatic urethral lift increased from <1% in 2014 to 10.4% in 2018. Compared to transurethral resection of the prostate and prostate photovaporization, prostatic urethral lift was associated with a lower odds of readmission at 30 (OR 0.58, p <0.01) and 90 (OR 0.55, p <0.01) days and a higher odds of retreatment within 2 years of followup (OR 1.78, p <0.01). CONCLUSIONS: Providers have rapidly adopted prostatic urethral lift which accounted for more than 1 in 10 endoscopic procedures captured for BPE/LUTS in 2018. Men treated with prostatic urethral lift are readmitted less within 30 and 90 days but are more likely to be retreated within 2 years of their index procedure as compared to men treated with transurethral resection of the prostate or prostate photovaporization.
引用
- Gaffney CD, Basourakos SP, Al Hussein Al Awamlh B, et al. Adoption, Safety, and Retreatment Rates of Prostatic Urethral Lift for Benign Prostatic Enlargement. J Urol. 2021. PMID: 33793296. doi:10.1097/JU.0000000000001757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。